[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-density\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-density":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,54,91,123,156,185,208,232,263,286,308,336],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100589043","metabolic-health-bones-and-nuts-during-weight-loss-in-adults-100589043",false,"NCT06949280","Metabolic Health, Bones and Nuts During Weight Loss in Adults","Metabolic Health, Bones and Nuts Sources of Fatty Acids During Weight Loss in Adults","BERN","Inclusion Criteria:\n\n* Men and postmenopausal women (\\>2 years since last menses), ages 50-75 years\n* Body mass index (25-42 kg\u002Fm2) or evidence of pre-clinical obesity.\n* Agree to be randomly assigned to consume a daily peanut snack or nut-free snack for 24 weeks\n* Must attend on-site visits (about 10) in New Brunswick, NJ, USA (transportation\u002Freimbursement for travel not included)\n\nExclusion Criteria:\n\n* Peanut allergies or intolerances\n* Participants with \\>5% weight loss in the past 6 months or extreme dietary\u002Fphysical activity habits\n* An inability to follow the experimental intervention or to perform the required specimen collections.\n* Individuals with significant psychiatric or food disorders.\n* Current diagnosis, or history of cancer in past 3 years.\n* Current diagnosis or history of bone diseases, type I or II diabetes, gastrointestinal disease, hyperparathyroidism, untreated thyroid disease, significant immune, hepatic, cardiac, or renal disease.\n* Uncontrolled hypertension or hyperlipidemia in abnormal ranges.\n* History of surgery in the past 6 months or surgical procedure for weight loss in the past 3 years.\n* Regular use of medications that affect bone metabolism, including bisphosphonates or hormone replacement.\n* Regular use of medications for that affect the gastrointestinal tract including incretin mimetics, cholecystitis, urinary tract infection, severe organic diseases including coronary heart disease, myocardial infarction, infectious diseases including pulmonary tuberculosis and AIDS.\n* Antibiotic use in the past month\n* Alcohol or illicit drug abuse\n* Any other condition deemed by the Research Physician that would prevent participation in the study, e.g. participation in another clinical research project that may interfere with the results of this study.\n* Participation in another clinical interventional research trial",true,"ALL","50 Years","75 Years",{"count":22,"type":23},44,"ESTIMATED","INTERVENTIONAL",[26],"NA","The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice but are not consumed frequently enough in older adults. Studies have shown that regular nut consumption is associated with lower adiposity and reduced weight gain, and several dietary pattern studies indicate that nuts and legumes are associated with better bone health. In addition, our preliminary translational data indicates that a higher monounsaturated fatty acid (MUFA) intake is associated with improved bone mineral density (BMD) and quality. Given these findings, the proposed study aims to examine the impact of consuming peanut products on bone health, metabolic health (e.g., serum glucose, insulin, lipids and inflammation), markers of brain and sleep health, and physical function in overweight and obese older adults before and after a six-month weight loss intervention using a randomized controlled design. The results of this study have the potential to provide valuable insights into the role of peanuts as a sources of fatty acids in promoting health and preventing disease in at-risk adults.",[29,30,31],"Weight Loss","Bone Density","Obesity and Overweight",[33,34,35,36,37,38,39,40],"weight loss","adults","bone","cognition","metabolic health","sleep","peanut","Monounsaturated fatty acid","RECRUITING","2026-05-08",{"date":44,"type":45},"2026-05-13","ACTUAL",{"date":47,"type":45},"2025-10-30",{"date":49,"type":23},"2027-12-31",{"name":51,"class":52},"Rutgers, The State University of New Jersey","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":62,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":24,"phases":66,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100640472","bed-rest-with-a-short-cervix-on-preterm-birth-100640472","NCT07577388","Bed Rest With a Short Cervix on Preterm Birth","BEWISE - Bed Rest With a Short Cervix on Preterm Birth","BEWISE","Pregnant women with gestational age 20+0 to 33+6\n\n* Cervical length \\\u003C 25 mm in singleton pregnancies and \\\u003C 30 mm in multiple pregnancies\n* Above 18 years of age\n* Reads and understands Danish or English","FEMALE","18 Years",{"count":65,"type":23},6000,[26],"Maternal AR has long been used to prevent PTB. However, definitions of AR vary widely, ranging from complete bed rest to partial limitation of physical activity for one or more hours daily.\n\nThe use of maternal AR to prevent preterm birth is largely based on observational evidence linking strenuous physical activity to an increased risk of preterm birth, and the assumption that reduced activity may decrease myometrial activity. However, the existing evidence on the clinical effects of AR remains limited and has not demonstrated a reduction in preterm birth or a delay in deliv-ery. In contrast, some studies suggest a potential increase in preterm birth following AR and instead significant adverse maternal and fetal effects.\n\nThe overall aim of this study is to compare gestational age at birth in women with a short cervix who are prescribed AR compared with women with a short cervix who are not prescribed AR (NAR).\n\nThe primary hypothesis is that NAR is non-inferior to AR in prolonging pregnancy in women with a short cervix.\n\nSecondary hypotheses are that, compared with AR, NAR is associated with higher level of physical activity, lower risk of maternal depression, and reduced risk of loss of maternal bone mineral density.\n\nThrough the BEWISE study, we wish to implement a change in the Danish national clinical practice regarding AR from recommending AR in risk groups (current practice) to no longer recommending AR as part as routine care (new practice). We will evaluate this change in clinical practice by prospectively collecting data from women both before and after implementation of the new recommendation. The transition from AR to NAR will be implemented sequentially in each Danish region using a randomised stepped-wedge (SW) cluster design, with each region constituting a cluster. The order in which regions transition is determined by randomisation. Each region will adopt the new recommendation at 3-month intervals, resulting in full national transition from AR to NAR within 12 months Eligible participants are pregnant women in gestational age 20+0 to 33+6 and cervical length \\\u003C 25 mm in singleton pregnancies and \\\u003C 30 mm in multiple pregnancies. Participants must be above 18 years of age and be able to read and understand Danish or English. There are no exclusion criteria.\n\nThe primary outcome is gestational age in days (continuous).",[69,70,71,72,73,74,75,76,77,78,79,80,30],"Preterm Birth","Cervical Insufficiency","Bed Rest","Pregnancy Complications","Immobilization","Depression, Postpartum","Pregnancy Outcome","Infant, Premature","Uterine Cervical Incompetence","Premature Birth","Obstetric Labor, Premature","Physical Activity","NOT_YET_RECRUITING","2026-05-03",{"date":84,"type":45},"2026-05-11",{"date":86,"type":23},"2026-05-01",{"date":88,"type":23},"2029-05-01",{"name":90,"class":52},"Julie Glavind",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":62,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":24,"phases":102,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100593723","phase-2-role-of-estrogen-on-skeletal-outcomes-in-fha-100593723","NCT07010146","Role of Estrogen on Skeletal Outcomes in FHA","Role of Estrogen Formulation and Route of Delivery on Skeletal Outcomes in Functional Hypothalmic Amenorrhea","Inclusion Criteria:\n\n* Females, age 14-30 years, skeletally mature with bone age ≥ 14 years (only 2% of growth left)\n* Women of reproductive age: use of an effective non-hormonal contraceptive method or a progestin releasing intrauterine device (no systemic skeletal effects) for study duration if sexually active. Note: Women who receive a progestin implant for contraception after study enrollment will be allowed to continue and will not be excluded from study.\n* Biochemical criteria: negative βHCG (pregnancy test), TSH within 2x the upper limit of normal, prolactin \\\u003C10 ng\u002FmL above upper limit of normal, potassium between 3.0-5.0, ALT ≤3 times upper limit of normal, LDL ≤190 mg\u002Fdl.\n* Patients with known hypothyroidism will be included if appropriately treated with levothyroxine and have a TSH within 2x the upper limit of normal for at least a month preceding the baseline study visit.\n* Menstrual criteria: \\\u003C 3 menses in the preceding 6 months.\n\nExclusion Criteria:\n\n* Disease other than FHA known to affect bone, including untreated thyroid dysfunction, Cushing's disease, renal failure, diabetes mellitus\n\n  1. Primary thyroid dysfunction will be defined as a TSH level more than 2X the upper limit of normal per given reference range with unknown thyroid antibody status, or an abnormal TSH if known positive antibodies.\n  2. Patients with hypothyroidism will be excluded if not appropriately treated with levothyroxine and if they do not have a TSH level within 2X the upper limit of normal for at least a month preceding the baseline study visit, given possible effects on the reproductive axis and bone.\n* Use of other medications known to affect bone metabolism within 3 months of the study (other than calcium and vitamin D supplementation)\n* Substance use disorder; current smoker (\\>10 cigarettes per day)\n* Pregnant, planning to become pregnant within 12 months of the end of treatment and\u002For breastfeeding\n* Hypertension or use of anti-hypertensive medications\n* Other conditions causing oligo-amenorrhea such as PCOS, premature ovarian insufficiency\n* Known sensitivity or absolute contraindication to any component of study medications (high risk thromboembolic disease, breast cancer or other estrogen- or progestin-sensitive cancer, liver tumors, acute viral hepatitis, decompensated cirrhosis, undiagnosed abnormal uterine bleeding\n* BMI ≥ 25 kg\u002Fm2 (efficacy of the contraceptive patch being used in the study is lower at higher BMIs)","14 Years","30 Years",{"count":101,"type":23},150,[103],"PHASE2","The purpose of this study is to assess whether the natural form of estrogen (17-beta estradiol) given as a patch so that it is absorbed through your skin, is better at improving bone strength over 1 year than natural estrogen (17-beta estradiol) taken by mouth, or a synthetic form oestrogen (ethinyl estradiol) given as a patch that also provides birth control.\n\nParticipants will:\n\n1. Take estrogen for 1 year either (i) in its natural form as a patch twice a week (and progesterone by mouth for 12 days of each month), or (ii) in its natural form as a pill daily (and progesterone by mouth for 12 days of each month), or (iii) in a synthetic form as a birth control patch weekly for 3 weeks with 1 week off the patch. You will not be able to choose which form of estrogen you will receive as this will be assigned to you based on a pre-existing randomization sequence (like the flip of a coin)\n2. Take provided calcium and vitamin D supplements\n3. Attend 4 study visits over 12 months with two at the beginning and then every 6 months that include:\n\n   * History and Physical Exams\n   * Lab Work\n   * Imaging studies\n   * Questionnaires\n   * Dietary recalls",[106,30,107],"Bone Strength","FHA (Functional Hypothalamic Amenorrhea)",[109,110,111,112],"Estrogen","Functional hypothalamic amenorrhea","Transdermal","Oral","2026-04-15",{"date":115,"type":45},"2026-04-17",{"date":117,"type":45},"2025-10-01",{"date":119,"type":23},"2030-05-31",{"name":121,"class":52},"University of Virginia",2,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":18,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":24,"phases":134,"briefSummary":135,"conditions":136,"keywords":141,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":53},"100585558","phase-2-bone-metabolism-in-12-21-year-olds-undergoing-glucagon-like-peptide-glp-1-receptor-agonist-therapy-100585558","NCT06903923","Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy","Bone Metabolism in Adolescents Undergoing GLP-1 Receptor Agonist Therapy","Inclusion Criteria:\n\n* • Adolescents and young adults with obesity 12-21 years old starting GLP-1 RA therapy (except for dulaglutide or exenatide) or followed with 'usual' care.\n* Diagnosis of obesity (BMI ≥ 95th percentile for age and sex). The FDA has approved the use of GLP-1 RAs (liraglutide and semaglutide) for adolescents ≥ 12 years old with BMI ≥ 95th percentile for age and sex, and tirzepatide for adults with obesity. Those in the GLP-1 RA arm must have demonstrated efforts at weight loss with 'usual' care, and consistent compliance with appointments and recommendations.\n* Participants must demonstrate sufficient maturity, psychological stability and cognitive capacity to recognize the significance of being on medical therapy and implement required behavioral changes\n* Patients taking orlistat as a precursor to GLP-1 RA therapy due to insurance requirements may be included given minimal effects on weight.\n* Use of the following contraceptive methods is permitted: Combine oral contraceptives (COCs); continuous oral progestin; Progestin-releasing intrauterine device (IUD); Progestin implant; transdermal patch.\n* Patients with celiac disease will be included if the condition is well controlled and they are on a gluten free diet with normal 25(OH)D levels confirmed by clinical labs within 3 months of enrollment in the study. If a patient does not have recent 25(OH)D results, we will add this to the screening labs.\n\nExclusion Criteria:\n\n* • Current or previous history of pregnancy and breast feeding.\n* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 if in the GLP-1 RA group.\n* \\> 5 kg weight loss over 3 months given the known impact of significant weight loss on bone density.\n* Use of dulaglutide and exenatide (of the GLP-1 RAs) given minimal weight loss with these drugs.\n* Use of medications such as metformin, phentermine, or topiramate that may cause weight loss, or obesogenic antipsychotic medications if treated for \\\u003C3 months, or if dosage is not stable for \\>2 months.\n* Medications other than calcium or vitamin D that affect bone, such as systemic glucocorticoids, phenytoin, phenobarbitone (unless there is a washout period of 3 months prior to enrollment if discontinuation is medically permissible)\n* Female participants on hormonal contraception will be excluded if this involves use of depot medroxyprogesterone acetate (DMPA). DMPA has profound deleterious effect on bone density, which could confound study outcomes related to bone health. Rationale: DMPA has a well-documented deleterious effect on bone density, which could confound study outcomes related to bone health or metabolic parameters.\n* Untreated thyroid dysfunction or on stable dose for \\\u003C3 months. Primary thyroid dysfunction will be defined as: a TSH ≥ 10 IU\u002FL or low per given reference range with unknown thyroid antibody status, or an abnormal TSH if known positive antibodies. Patients with known hypothyroidism will be included if appropriately treated with levothyroxine and have a normal TSH. For patients with secondary hypothyroidism (deficient production of TSH from the pituitary gland causing hypothyroidism), normal free T4 concentrations (and not TSH alterations) will be used for study inclusion, and recent adjustments in the levothyroxine dose will be permissible as long as free T4 concentrations are in the normal range at dose adjustment (as dose adjustments are often made to get free T4 concentrations in the upper half of the normal range when assessed levels are in the lower half of the normal range). Patients with hyperthyroidism will be excluded given known deleterious effects on both weight and bone metabolism.\n* Medical conditions known to impact weight or bone density, such as chronic gastrointestinal disorders (including inflammatory bowel disease), other inflammatory conditions, such as rheumatoid arthritis or ankylosing spondylitis, untreated thyroid disease, and hypercortisolemia.\n* HbA1C \\>8% (to avoid deleterious effects on bone from uncontrolled T2DM).\n* Smoking \\>10 cigarettes\u002Fday given deleterious effects on bone; substance abuse per DSM-5.\n* Weight \\>450 lbs due to limits for DXA scanners.\n* History of metabolic and bariatric surgery.\n* Judged by the investigators to be inappropriate for the study for other reasons not detailed above.","12 Years","21 Years",{"count":133,"type":23},120,[103],"The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 receptor agonists (GLP-1RAs) as compared to those with similar weight followed by lifestyle management.\n\nParticipants will:\n\n* Take GLP-1RA as prescribed or continue to work on lifestyle management for weight loss\n* Take provided calcium and vitamin D supplements\n* Attend 6 study visits over 24 months with two at the beginning and then every 6 months that include:\n\n  * History and Physical Exams\n  * Lab Work\n  * Imaging studies\n  * Questionnaires\n  * 24-hour dietary recalls",[137,106,138,139,30,140],"Obesity in Children","GLP - 1","Lifestyle Modification","Obesity",[142,143,144,145,146,147,148,149],"obesity","obesity in children","bone strength","GLP-1","Lifestyle modification","bone density","semaglutide","liraglutide",{"date":115,"type":45},{"date":152,"type":45},"2025-07-31",{"date":154,"type":23},"2030-04-30",{"name":121,"class":52},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":17,"sex":18,"minAge":63,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":24,"phases":167,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":53},"100595386","early-phase-1-topic-simvastatin-for-bone-regeneration-100595386","NCT07031778","Topic Simvastatin for Bone Regeneration","Efficacy of Topical Application of Simvastatin in Bone Regeneration","SM","Inclusion Criteria:\n\n* Anesthetic risk ASA I-II.\n* Patients with the adjacent tooth in the mouth (37 or 47).\n* Third molars with fully developed roots.\n* Mandibular third molars included or semi-included.\n* With indication for extraction.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Chronic smokers.\n* Patients with decompensated metabolic disease.\n* Patients with motor difficulties that prevent or hinder hygiene.\n* Patients who are using statins to treat hypercholesterolemia.\n* Patients under treatment with drugs that could affect the osseointegration process such as chemotherapy drugs, bisphosphonates, corticosteroids or immunosuppressants.\n* Patients with metabolic bone diseases or who have undergone radiotherapy in the last five years.","40 Years",{"count":166,"type":23},90,[168],"EARLY_PHASE1","The goal of this clinical trial is to evaluate the efficacy of topical application of simvastatin in bone regeneration in the maxillae, in the reduction of dimensional bone changes, using mandibular third molar surgery as a model and assessing bone healing at 12 weeks. We will also compare the two forms of intralveolar topical administration currently used to assess which is the best form of administration. The main questions it aims to answer are:\n\n* Can the topical application of simvastatin, used as a preservation material, improve the variations with respect to bone dimensions and density that occur after tooth extraction.\n* Can topical application of SM improve soft tissue healing.\n* Does the topical application of SM produce changes with respect to postoperative variables of pain, inflammation or trismus.\n* What is the best vehicle for topical SM administration?\n\nFor this purpose, the investigators will randomly place 4 topical treatment options in the postextraction alveoli:\n\n* SM in gel form\n* collagen sponge impregnated with saline solution containing 10 mg of SM\n* collagen sponge with placebo gel. All patients will undergo postoperative CBCT, which will be repeated at 12 weeks.\n\nIn addition, inflammation, trismus and pain variables will be measured preoperatively, at 24 hours, 3 and 7 days.",[171,30],"Dimensional Changes",[173,147,174,175],"simvastatin","dimensional changes","cbct scan","2025-06-12",{"date":178,"type":45},"2025-06-22",{"date":180,"type":45},"2025-01-07",{"date":182,"type":23},"2025-12-31",{"name":184,"class":52},"Universidad de Granada",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":18,"minAge":63,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":53},"100592208","effect-of-long-term-use-of-tenofovir-tdf-on-bone-density-in-patients-with-chronic-hepatitis-b-100592208","NCT06990438","Effect of Long-Term Use of Tenofovir (TDF) on Bone Density in Patients With Chronic Hepatitis B","Inclusion Criteria:\n\n\\-\n\nInclusion Criteria:\n\nAdult male or female patients aged 18 to 60 years.\n\nDiagnosed as HBV-positive.\n\nLong-term use of Tenofovir Disoproxil Fumarate (TDF) for more than five years.\n\nExclusion Criteria:\n\nPresence of other chronic liver diseases.\n\nDiagnosed with Chronic Kidney Disease (CKD), regardless of etiology.\n\nPatients who refuse to participate in the study.\n\nPatients on combination therapy, including:\n\nInterferon and Nucleoside analogue combination therapy.\n\nMultiple nucleoside analogue combination therapy.\n\n\\-","60 Years",{"count":193,"type":23},172,"OBSERVATIONAL","This study aims to evaluate the effect of long-term use of Tenofovir Disoproxil Fumarate (TDF) on bone density in patients with chronic hepatitis B virus (HBV) infection. Tenofovir is a widely used antiviral medication for the treatment of HBV. While it is generally well tolerated, some studies have reported potential adverse effects on bone mineral density, particularly with long-term use.\n\nThe objective of this research is to assess whether extended TDF therapy is associated with reduced bone density or increased risk of osteopenia or osteoporosis in adult patients with chronic HBV infection. The study will involve clinical evaluation and radiological assessment of bone health using dual-energy X-ray absorptiometry (DEXA) scans, as well as relevant biochemical markers.\n\nThis investigation will provide important data on the long-term safety profile of Tenofovir in relation to bone health and help guide future clinical decisions for the management of chronic hepatitis B.",[197,30,198],"Tenofovir Disoproxil Fumarate","Chronic HBV Infection","2025-05-17",{"date":201,"type":45},"2025-05-25",{"date":203,"type":23},"2025-05-22",{"date":205,"type":23},"2026-06-01",{"name":207,"class":52},"Assiut University",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":17,"sex":62,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":24,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":122},"100591681","reference-curves-for-bone-mineral-density-and-body-composition-in-women-aged-20-89-100591681","NCT06983587","Reference Curves for Bone Mineral Density and Body Composition in Women Aged 20-89","Study to Establish Reference Curves for Bone Mineral Density (BMD) and Body Composition (BC) in Women Aged 20-89 MONIKA","MONIKA","Inclusion Criteria:\n\n* Ethnic origin European, Middle Eastern, North African and whose 2 parents are from Europe, Middle East, North Africa only as there is a difference in BMD according to ethnicity\n* Person affiliated to or benefiting from a social security scheme\n* Free, informed consent signed by the participant and the investigator (on the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Patients presenting one of the following major risk factors:\n* Fragility fracture defined as a spontaneous or low-kinetic fracture (≤ one fall from height)\n* Hip fracture in a first-degree relative\n* Early menopause (\\\u003C age 40), Hysterectomy (complete \\\u003C age 40), Primary amenorrhea (absence of menstruation before age 15), Current amenorrhea of more than 3 months without contraceptive if patient is under age 40\n* Treatments : Prolonged corticosteroid therapy \\> 3 months or \\> 1 g (cumulative dose)\n* Immobilization of more than 3 months, less than 12 months old\n* Patients presenting one of the following pathologies affecting bone, muscle or adipose tissue:\n* Chronic inflammatory bowel disease (IBD) (Crohn's disease, ulcerative colitis) and untreated celiac disease\n* Renal insufficiency on dialysis or patients with nephrology follow-up\n* Known hypercalciuria\n* Osteomalacia, rickets, osteogenesis imperfecta\n* Osteopathy (Paget's disease, osteopetrosis, etc.)\n* Chronic inflammatory rheumatism\n* Haemopathy, neoplasia\n* Hepatic insufficiency or chronic hepatitis\n* Endocrinopathy: dysthyroidism, hypogonadism, hypercorticism, untreated acromegaly.\n* Anorexia nervosa\n* Hyperparathyroidism (even if controlled)\n* History of digestive surgery (bariatric, gastrectomy, digestive resection other than appendectomy, etc.)\n* History of organ transplant\n* Chronic infectious disease (HIV, etc.)\n* Weight loss of more than 10 kg in the last 6 months\n* Paresis, marked lameness or unloading of a limb or prolonged immobilisation of more than one month in the last 12 months\n\nAll patients on any treatment that may affect bone mass or body composition:\n\n* Biphosphonates (Alendronate (Fosamax® and generics), Risedronate (Actonel® and generics), Zoledronate (Aclasta® and generics)\n* Teriparatide (Forsteo®)\n* Denosumab (Prolia®)\n* Selective oestrogen receptor modulator (Clomifen, Tamoxifen, Toremifen, Raloxifen)\n* Anabolic steroids.\n* Strontium ranelate\n* Carbamazepine\n* Phenobarbital\n* Immunosuppressants\n* Antiepileptics\n\nAll patients with one of the following anomalies in the measurement area:\n\n* Major deformities of the wrist, hip or vertebrae\n* Compression of the vertebral bodies, cementoplasty\n* Prosthesis, implant (breast, buttock, etc.), foreign body\n* Hip paraosteoarthropathy\n* Injection of radiological contrast product, barium enema, nuclear medicine examination within 10 days\n\nMiscellaneous :\n\n* Intensive sport (more than 10 h\u002Fweek).\n* Extreme BMI (BMI \\\u003C 18, BMI \\> 35 kg\u002Fm²).\n* Loss of autonomy\n* Pregnant, parturient or breast-feeding woman\n* Participation in an interventional study involving a drug or medical device or a category 1 RIPH in the 3 months prior to inclusion.","20 Years","89 Years",{"count":219,"type":23},425,[26],"Up-to-date normalcy curves for bone mineral density and body composition (fat and lean mass), are currently lacking. DMS IMAGING is therefore financing the MONIKA study, with Nîmes University Hospital as sponsor.\n\nSome 425 healthy female volunteers aged 20 to 89 will be recruited from three centers (Nîmes, Montpellier and Lyon). A bone density scan at various bone sites (femur, rachis, radius and whole body) will provide up-to-date normalcy curves for bone mineral density as well as body composition (fat and lean mass). These measurements should help to better understand bone physiology and the links that may exist between bone tissue and muscle and adipose tissue.\n\nThis is a prospective multicenter cross-sectional descriptive study of healthy female volunteers. The study population is made up of healthy female volunteers from Europe, the Middle East and North Africa aged between 20 and 89, stratified into 7 age groups.",[30],"2025-05-14",{"date":225,"type":45},"2025-05-21",{"date":227,"type":23},"2025-06-01",{"date":229,"type":23},"2029-09",{"name":231,"class":52},"Centre Hospitalier Universitaire de Nīmes",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":18,"minAge":63,"maxAge":4,"enrollmentInfo":239,"targetDuration":241,"studyType":194,"phases":4,"briefSummary":242,"conditions":243,"keywords":246,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":53},"100579891","investigating-the-relationship-between-temporal-bone-ct-bone-density-and-hearing-loss-in-otosclerosis-patients-100579891","NCT06830187","Investigating the Relationship Between Temporal Bone CT, Bone Density, and Hearing Loss in Otosclerosis Patients","Radiological and Audiological Correlation in Otosclerosis: a Prospective Case-Control Study Evaluating Temporal Bone CT, Bone Mineral Density, and Hearing Loss","Inclusion Criteria (Otosclerosis Group):\n\n* Adults diagnosed with otosclerosis based on audiological and clinical assessment\n* Patients with available high-resolution CT scans and audiological data\n* Individuals who have undergone stapedectomy or stapedotomy surgery\n* Availability of bone mineral density and serum vitamin D data\n\nInclusion Criteria (Control Group):\n\n* Patients without otosclerosis but with temporal CT imaging for other indications\n* No history of conductive or mixed hearing loss\n* Availability of BMD and vitamin D data\n\nExclusion Criteria:\n\n* History of primary metabolic bone diseases (osteoporosis, Paget's disease)\n* Use of medications affecting bone metabolism (bisphosphonates, corticosteroids)\n* History of chronic otitis media or prior ear surgeries\n* Patients who received head and neck radiotherapy",{"count":240,"type":23},86,"2 Months","The goal of this observational case-control study is to evaluate the relationship between temporal bone computed tomography (CT) findings, bone mineral density (BMD), and audiological parameters in adults diagnosed with otosclerosis. The main questions it aims to answer are:\n\nIs there a correlation between temporal bone CT density values and the severity of hearing loss in otosclerosis? Do bone mineral density and serum vitamin D levels differ between otosclerosis patients and individuals without otosclerosis? Researchers will compare patients diagnosed with otosclerosis to a control group without otosclerosis to determine if CT-based density variations are associated with disease severity and systemic bone metabolism markers.\n\nParticipants who have already had a temporal bone CT scan as part of their routine clinical evaluation will undergo:\n\nBone mineral density (BMD) assessment via dual-energy X-ray absorptiometry (DEXA) Serum vitamin D level measurement Audiological testing, including pure tone audiometry and speech discrimination tests This study aims to improve the diagnostic and prognostic understanding of otosclerosis by integrating imaging, metabolic, and audiological data.",[244,30,245],"Otosclerosis of Middle Ear","Vitamin D Deficiency",[247,248,249,250,251,252,253],"Otosclerosis","Temporal Bone CT","Bone Mineral Density (BMD)","Serum Vitamin D","Audiology","Stapedectomy","Hounsfield Units","2025-02-19",{"date":256,"type":45},"2025-02-20",{"date":258,"type":45},"2022-01-01",{"date":260,"type":23},"2025-05-01",{"name":262,"class":52},"İbrahim Emir Yeşil",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":17,"sex":62,"minAge":216,"maxAge":217,"enrollmentInfo":271,"targetDuration":4,"studyType":24,"phases":273,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":122},"100568591","mediating-role-of-myokines-in-the-dialogue-between-muscle-and-bone-tissue-in-a-population-of-healthy-women-aged-20-89-years-100568591","NCT06683222","Mediating Role of Myokines in the Dialogue Between Muscle and Bone Tissue in a Population of Healthy Women Aged 20-89 Years","Analysis of the Mediating Role of Myokines in the Dialogue Between Muscle and Bone Tissue in a Population of Healthy Women Aged 20-89 Years","MyOs","Inclusion Criteria:\n\n* Self-reported Caucasian ethnicity (Europe, Middle East, North Africa) only as there is a difference in BMD by ethnicity.\n* Person affiliated with or benefiting from a social security scheme.\n* Free, informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Fragility fracture defined as a spontaneous or low-kinetic fracture (≤ one fall from height).\n* Early menopause (\\\u003C 40 years), hysterectomy (complete \\\u003C 40 years), primary amenorrhea (absence of menstruation before 15 years), current amenorrhea of more than 3 months without contraceptive if the patient is less than 40 years old.\n* Patients on treatments: prolonged corticosteroid therapy \\> 3 months or \\> 1 g (cumulative dose).\n* Immobilization of more than 3 months, less than 12 months old.\n* Hip fracture in a first-degree relative.\n\nPatients with any of the following pathologies affecting bone, muscle or adipose tissue:\n\n* Inflammatory bowel disease (IBD: Crohn's disease, ulcerative colitis) and untreated celiac disease.\n* Renal insufficiency on dialysis or patients with nephrology follow-up.\n* Known hypercalciuria.\n* Osteomalacia, rickets, osteogenesis imperfecta.\n* Osteopathy (Paget's disease, osteopetrosis, etc.).\n* Chronic inflammatory rheumatism.\n* Hemopathy, neoplasia.\n* Hepatic insufficiency or chronic hepatitis.\n* Endocrinopathy: diabetes, dysthyroidism, hypogonadism, hypercorticism, untreated acromegaly.\n* Anorexia nervosa.\n* Hyperparathyroidism (even controlled).\n* History of digestive surgery (bariatric, gastrectomy, digestive resection other than appendectomy, etc.).\n* History of organ transplantation.\n* Chronic infectious disease (HIV, etc.).\n* Weight loss of more than 10 kg within 6 months.\n* Paresis, marked lameness or unloading of a limb, or prolonged immobilization of more than one month in the last 12 months.\n* Patients on treatments that may affect bone mass or body composition:\n* Biphosphonates (Alendronate (Fosamax® and generics), Risedronate (Actonel® and generics), Zoledronate (Aclasta® and generics).\n* Teriparatide (Forsteo®).\n* Denosumab (Prolia®)\n* Selective estrogen receptor modulators (Clomifene, Tamoxifene, Toremifene, Raloxifene).\n* Anabolic steroids.\n* Strontium ranelate.\n* Carbamazepine.\n* Phenobarbital.\n* Immunosuppressants.\n* Patients on anti-epileptics.\n* Patients with any of the following abnormalities in the measurement area:\n* Major deformities of the wrist, hip or vertebrae.\n* Compression of vertebral bodies, cementoplasty.\n* Prosthesis, implant (breast, buttock, etc.), foreign body.\n* Hip paraosteoarthropathy.\n* Injection of radiological contrast medium, barium enema, nuclear medicine examination within 10 days.\n* Intensive sport (more than 10 h\u002Fweek).\n* Extreme BMI (BMI \\\u003C 18, BMI \\> 35 kg\u002Fm²).\n* Loss of autonomy.\n* People with neurodegenerative disorders affecting their ability to give consent.\n* Pregnant, parturient or breast-feeding women.\n* Participation in an interventional study involving a drug or medical device or a category 1 RIPH within 3 months prior to inclusion.",{"count":272,"type":23},280,[26],"The main hypothesis is that muscle acts on bone tissue via the secretion of myokines (myostatin, follistatin, irisin). This is based on previous results showing that muscle mass in different patient populations with very different body mass indexes (anorexic or obese patients) is significantly and independently associated with bone mineral density.",[30],[277],"Myokines","2024-11-27",{"date":280,"type":45},"2024-11-29",{"date":282,"type":45},"2024-11-06",{"date":284,"type":23},"2029-09-30",{"name":231,"class":52},{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":17,"sex":18,"minAge":63,"maxAge":164,"enrollmentInfo":294,"targetDuration":4,"studyType":24,"phases":296,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":306,"leadSponsor":307,"locationsCount":4},"100567121","early-phase-1-osteoimplant-and-bone-healing-100567121","NCT06664060","Osteoimplant and Bone Healing","Efficacy of Two Nutritional Supplements on Healing and Bone Density in the Jaws","Osteocic","Inclusion Criteria:\n\n* Patients presenting both lower third molars.\n* Adult patients between 18 and 40 years of age.\n* Anaesthetic risk ASA I-II (American Society of Anaesthesiologists classification) \\[14\\].\n* Absence of drug or food allergies that could compromise our study (e.g. egg).\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Age not between 18-40 years.\n* Pregnant or breastfeeding women.\n* Presenting decompensated metabolic disease.\n* Poor periodontal status (≥10% plaque index and bleeding index).\n* Patients who have undergone radiotherapy in the last five years.\n* Patients who will not comply with the study guidelines.\n* Unsigned informed consent.\n* History of allergy to any study medication or related drugs (e.g. egg).\n* Patients with a history of renal colic.",{"count":295,"type":23},60,[168],"In view of the above and the possible improvements in terms of postoperative morbidity and tissue repair in oral surgery, this study is justified, the general objective of which would be:\n\n'To evaluate the efficacy of perioperative oral administration of two nutritional supplements based on vitamins and antioxidants (Osteoimplant Complex® and Osteoimplant®), using mandibular third molar surgery as a study model, assessing postoperative symptomatology and bone density'.\n\nThe null hypothesis of this study is: 1) the administration of the perioperative nutritional complex (Osteoimplant Complex® and Osteoimplant®) did not improve postoperative symptoms and 2) neither did it increase bone density after lower third molar extraction.",[171,30],[300,301,147,174],"vitamin d","vitamin c","2024-10-27",{"date":304,"type":45},"2024-10-29",{"date":180,"type":23},{"date":182,"type":23},{"name":184,"class":52},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":17,"sex":315,"minAge":19,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":24,"phases":318,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":53},"100565614","whole-body-vibration-in-middle-aged-men-100565614","NCT06644469","Whole Body Vibration in Middle Aged Men","Effects of Whole-Body Vibration on Bone Mineral Density, Hand Grip Strength, and Vitamin D Levels in Middle-Aged Men: a Preliminary Clinical Trial","Inclusion Criteria:\n\n* Male participants aged 50 years or older\n* Participants with physical activity or exercise program involvement\n* Participants with no history of serious medical conditions such as tumors, fractures, epilepsy, cardiac disease, or stroke within the past year.\n* Participants must be non-smokers and not receiving hormone or calcium supplement therapy\n\nExclusion Criteria:\n\n* Participants unable to stand on the WBV platform\n* Participants with conditions contraindicating vibration therapy\n* Participants participating in other clinical trials","MALE",{"count":317,"type":23},34,[26],"This study aims of this clinical trial is to evaluate the effect of an 8-week Whole Body Vibration (WBV) intervention on Bone Mineral Density (BMD), hand grip strength, and vitamin D levels in middle-aged men. Findings from this study will contribute to understanding whether WBV is a viable alternative to conventional exercise, especially for those with limitations in physical activity.\n\nStudy Objectives:\n\n• Primary Objective: To assess the effectiveness of an 8-week WBV intervention in improving BMD, hand grip strength, and vitamin D levels compared to a placebo intervention.",[30,321],"Muscle Weakness",[323,30,324,325,326],"Pilot Study","Vibration Therapy","Vitamin D","Muscle Strength","2024-10-16",{"date":329,"type":45},"2024-10-18",{"date":331,"type":23},"2024-10-15",{"date":333,"type":23},"2024-12-15",{"name":335,"class":52},"Jouf University",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":17,"sex":62,"minAge":63,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":194,"phases":4,"briefSummary":346,"conditions":347,"keywords":356,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":53},"100562876","the-impact-of-hormonal-contraceptive-use-and-lifestyle-factors-on-fracture-risk-and-bone-quality-in-young-female-adults-100562876","NCT06608862","The Impact of Hormonal Contraceptive Use and Lifestyle Factors on Fracture Risk and Bone Quality in Young Female Adults","The Impact of Hormonal Contraceptive Use, Body Composition, Muscular Strength and Iron Status on Fracture Risk and Bone Quality in Adult Females from 18-35 Years","FH","Inclusion Criteria:\n\n* 18 - 35 years\n* female\n* willing to participate under a pseudonym\n* occupational soldiers\n* free from chronic or acute musculoskeletal injury\n\nExclusion Criteria:\n\n* for the bioelectrical impedance: electronic implants like defibrillator, pregnancy","35 Years",{"count":101,"type":23},"The study on hand is based on a cross-sectional design and aims to acquire 1) descriptive data on the physical state and health condition of female soldiers in the German armed forces. 2) a possible influence of different contraceptive methods as well as physical activity, body composition, strength, nutrition, and hemoglobin levels on bone health should be investigated.",[348,349,350,351,352,353,326,30,354,80,355],"Osteoporosis","Osteopenia","Fracture Reduction","Body Composition","Nutrition","Hemoglobin","Contraception Behavior","Menstrual Irregularities",[357,358,359,360,361,362,363,364],"impact of lifestyle factors on bone quality","impact of hormonal contraceptive use on bone quality","impact of body composition on bone quality","impact of nutrition and energy balance on bone quality","impact of amenorrhea on bone quality","impact of physical activity on bone quality","impact of the occupation soldier on bone quality","impact of muscle strength on bone quality","2024-09-19",{"date":367,"type":45},"2024-09-23",{"date":369,"type":45},"2023-10-01",{"date":371,"type":23},"2026-07-31",{"name":373,"class":52},"Bundeswehr University Munich"]